

Do Drug Competency Assessments Work?

Suzanne M. Surowiec, PharmD, BCACP, Laura K. Sjoquist, PharmD, Jason W. Guy, PharmD
The University of Findlay College of Pharmacy, Findlay, OH



Key Take-Aways

- Unsuccessful model for drug competency assessment
- Too frequent testing of drug knowledge may overwhelm a learner and diminish ability to learn (a finding consistent with educational literature)
- Best practice for evaluating progress to drug knowledge mastery still needs to be determined

Background

- Competency-based design endorsed by 2016 accreditation standards including areas of drug therapeutic use and side effects
- Repeated practice via sequenced low-stakes assessments has been proposed as a means of ensuring mastery learning (i.e. full ability)
- No published models evaluate how best to assess progress towards drug knowledge competency

Objective


To evaluate the effectiveness of a novel drug competency assessment strategy in third professional year pharmacy students

Master Drug List

- 461 medications covering 9 domains:

Cardiology (C)	Respiratory (R)	Endocrine (E)
Immunology (I)	Infectious disease (ID)	Gastrointestinal (GI)
Renal	Pain	Neurology-Psychiatry (NP)

- Content and relevance chosen via NAPLEX preparation materials, clinical pharmacist expert opinion, and consensus with 3 additional clinical pharmacists
- Drug Knowledge categories



Methods

Design: Phased retrospective comparison

- 3-phase drug competency assessment in spring 2022 using the institutional master drug list (**Figure 1**)
- 13 assessments including multiple choice and case-based questions asked student to recall pertinent medication information from the master drug list

9 low-stakes quizzes (2 attempts, on-your-own)

3 formative tests (lock-down browser)

- 30 questions each covering the 3 prior domains

1 summative comprehensive 60-question final

- To pass: must earn $\geq 73\%$
- If unsuccessful, 2 remediation attempts given (if none were successful, a zero recorded for score)

Analysis:


- Demographics, correlation and sensitivity analysis

Phased competency design (test group - spring 2022) vs. previous year's design (control group - spring 2021)

- Spring 2021 - only one practice exam and the final summative comprehensive competency
- Same between years, including pass threshold and proctoring

- Sub analysis with removal of failures between cohorts

Figure 1. Schematic of Assessment Design for Test Group (2022) and Control Group (2021)



Results

Table 1. Student Pharmacist Demographics

Student Cohort	Control - Spring 2021 N (%)	Test - Spring 2022 N (%)
Sample Size	43 (100)	48 (100)
Female	30 (69.7)	33 (68.8)
Race		
Caucasian	37 (86)	38 (79)
African American	2 (5)	5 (10)
Other	4 (9)	5 (10)

Table 2. Comparison of Performance Between Groups

Student Cohort	Control Group Mean (SD)	Test Group Mean (SD)	p-value	95% Confidence Interval
Final summative exam score	81.9 (9.3)	80.9 (10.5)	0.64	1.005 (-3.2, 5.2)
Exam score removing failed first attempts (i.e., scores <73%)	84.3 (7.1)	84.3 (7.4)	0.97	0.053 (-3.3, 3.4)


- The 2021 practice exam moderately correlated with final exam performance – statistically significant ($r = 0.62$, $p < 0.001$)
- Number of attempts on low stakes assessments - low correlation with final exam score in 2022 cohort ($r = 0.24$)

Discussion

Design didn't demonstrate improved drug knowledge

- Inconsistent with prior studies on small, low-stakes testing

Why we theorize it didn't work



Implementation Challenges

- High faculty and TA time spent writing, proofing, overseeing and assessing (>350 hours, 840 questions)
- Assessor mental workload with assessment rigor

Limitations

- Small changes in drug characteristic list between years
- Short term outcome vs. rotations/NAPLEX, etc.
- Grades only are one method to evaluate knowledge
- Generalizability

Conclusion and Next Steps

- Limitations to use of a layered drug competency assessment model – need to try other models

Next steps:

- Reduce detail volume on list
- Add a practice exam
- Consider other assessment types for documenting APPE drug knowledge readiness

References

1. Accreditation Council for Pharmacy Education. Accreditation Standards and Key Elements for the Professional Program in Pharmacy Leading to the Doctor of Pharmacy Degree: Standards 2016. Released 2015. Available online: <https://www.acpe-accredit.org/pdf/Standards2016FINAL.pdf> (accessed on 4 March 2023).
2. Divall, M.V.; Alston, G.L.; Bird, E.; Buring, S.M.; Kelley, K.A.; Murphy, N.L.; Schlesselman, L.S.; Stowe, C.D.; Szilagyi, J.E. A faculty toolkit for formative assessment in pharmacy education. *Am. J. Pharm. Educ.* 2014, 78, 160. <https://doi.org/10.5688/ajpe789160>.
3. Lazerson, J.; Rosenthal, J.; Glaubenskle, C.; Hunt, T.; Morgenstern, B.; Pamidimukkala, J.; Penn, D.M.; Rosenthal, K.; Sarsekeyeva, M.; Wrapp, S. Adaptation of the Roseman 6-point mastery learning model to the college of medicine program. *J. Med. Educ. Curric. Dev.* 2018, 5, 2382120518803111. <https://doi.org/10.1177/2382120518803111>.
4. Segarra, V.A.; Hughes, N.M.; Ackerman, K.M.; Grider, M.H.; Lyda, T.; Vigueira, P.A. Student performance on the test of scientific literacy skills does not change with assignment of a low-stakes grade. *BMC Res. Notes* 2018, 11, 422. <https://doi.org/10.1186/s13104-018-3545-9>.